These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 19363851)

  • 21. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S; Tomi Z; Gulliver W
    Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C; Carrascosa JM; Boada A
    Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of biologics in psoriasis: a review.
    Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
    Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the new clinical landscape for psoriasis: a comparative review of biologics.
    Sauder DN; Mamelak AJ
    J Cutan Med Surg; 2004; 8(4):205-12. PubMed ID: 16091996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM; Hallas SJ
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
    Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
    J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.